Oxford Biomedica plc (OTCMKTS:OXBDF) shares reached a new 52-week high during trading on Thursday . The stock traded as high as $17.07 and last traded at $17.06, with a volume of 1735 shares. The stock had previously closed at $16.35.
Several research analysts recently commented on OXBDF shares. Zacks Investment Research downgraded shares of Oxford Biomedica from a “buy” rating to a “hold” rating in a report on Wednesday, April 28th. Royal Bank of Canada reaffirmed an “outperform” rating on shares of Oxford Biomedica in a report on Tuesday, May 25th. Finally, Investec raised shares of Oxford Biomedica from a “sell” rating to a “hold” rating in a report on Friday, May 14th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Oxford Biomedica has a consensus rating of “Buy” and an average price target of $17.00.
The stock’s fifty day simple moving average is $14.95. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.06 and a quick ratio of 1.93. The stock has a market capitalization of $1.31 billion, a PE ratio of -163.50 and a beta of 1.13.
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes.
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.